Elanco Animal Health Reports Third Quarter 2026 Results
Elanco reported Q3 2026 revenue of $1.265 billion, up 11% year-over-year (9% organic constant currency), with adjusted EPS of $0.27 up 42% YoY and adjusted EBITDA of $243 million at a 19.5% margin. The company raised full-year guidance across the board — revenue to $5.155B-$5.18B, adjusted EBITDA to $1.05B-$1.065B (+17% at midpoint), and adjusted EPS to $1.17-$1.20 (+26% at midpoint) — while lifting its innovation revenue target to $1.275 billion. Growth was led by Pet Health (+14%) and innovation products: Zenrelia posted record revenue and a 7-point gain in U.S. JAK market share, while Credelio Quattro became Elanco's largest U.S.
Key figures
- Eps
- 0.04
- Revenue
- 1265000000
- Guidance
- FY2026 revenue $5.155B-$5.18B (raised from $5.09B-$5.14B); Adjusted EBITDA $1.05B-$1.065B (raised from $1.010B-$1.035B); Adjusted EPS $1.17-$1.20 (raised from $1.10-$1.16); Q4 revenue $1.19B-$1.215B
- Revenue Yoy
- 11%
- Adjusted eps
- 0.27
- Gross margin
- 56.9%
- Adjusted ebitda
- 243000000
- Adjusted eps yoy
- 42%
- Net leverage ratio
- 2.9x
- Adjusted net income
- 136000000
- Operating cash flow
- 216000000
- Reported net income
- 18000000
- Adjusted gross margin
- 56.1%
- Adjusted ebitda margin
- 19.5%
- Innovation revenue target
- $1.275 billion
- Organic cc revenue growth
- 9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.